



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 19th JULY 2017 AT
12.30pm

IN SEMINAR ROOM 8, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Dr L Rogan (LR)	Head of Medicines Commissioning NHS EL CCG
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr K Burch (KB)	Consultant Microbiologist ELHT
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)
Dr T McKenzie (TM)	GP, EL CCG
Dr Y Naheed	GP, EL CCG

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2017/090: APOLOGIES:

Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT

2017/091: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2017/092: MINUTES OF JUNE MEETING:

Accepted as a correct record.

2017/093: MATTERS ARISING:

2017/007: Formulary Updates – Sodium valproate – nothing received from LTH. CCG's have prepared letter for GP's with referral back criteria. Action now completed.

2017/041: Tolvaptan/Demeclocycline for Hyponatraemia – tolvaptan use should only be in oncology patients. Demeclocycline still has very small amount of prescribing in primary care – VG to discuss referral back to secondary care with endocrinology.

2017/061: LMMG Consultations: Psoriasis Primary Care Guideline – products mapped across to formulary, see also 2017/077

2017/077: LMMG Recommendations: Psoriasis Primary Care Guideline products mapped across to formulary, all except Betamethasone mousse are already included. Agreed to add betamethasone mousse (Bettamousse) to formulary.

2017/074: LMMG Consultations (for June): Nicotine replacement Therapy – see main agenda item (2017/096).

2017/078: Formulary Updates – Pivmecillinam – was discussed at Antimicrobial Stewardship Committee and a change to Green traffic light (from Amber) was supported. Other Public Health Service England recommendations concerning clinical assessment and use (or not) of dipsticks should also be included. Agreed to change pivmecillinam to green.

Pivmellinam is not currently included on standard sensitivity tests so will need to be requested at the time sample sent in.

2017/079: ELHE: Guidelines for the management of COPD
ELHE: COPD Rescue Pack information

Guideline wording has been amended to clarify use of antibiotics and exacerbations in the absence of purulent sputum in line with NICE. Concern expressed that many patients are now requesting rescue packs that may not be necessary or appropriate.

2017/078: Formulary Updates – Ondansetron – concern expressed that green was not appropriate for the hyperemesis indication. Traffic light changed to Amber for hyperemesis, remains green for all other indications.

2017/094: NEW PRODUCT REQUEST – FIASP (Fast Acting Insulin Aspartate)

Request made by Dr Christian for a new, fast acting insulin (aspartate) similar to Novorapid. The request has been referred to LMMG for review. ELMMB will wait for LMMG review.

Resolved: FIASP has been referred to LMMG for review.

2017/095: LMMG CONSULTATIONS (for Sept LMMG)

None received.

2017/096 LMMG RECOMMENDATIONS (from June LMMG)

Vitamin D Position Statement

Not accepted for use in ELHE.

Statement has differences in the paediatric section compared to current ELHE paediatric guideline, and no PIL is included in new position statement. Concerns were expressed from clinicians re blood test requirements at 3 months, and there was a suggestion to include the PHE recommendation that everyone should receive a daily dose of 10

microgram. ELHE guidelines (paediatric and adult) to be reviewed with LMMG position statement. Bring back to ELMMB when completed.

NRT Position Statement

Not accepted for use in ELHE. ELHE will continue to use the more detailed ELHE statement already approved which includes contact details of the BwD and EL services.

Generic Biosimilar Position Statement

Accepted for use in ELHE.

2017/097: FORMULARY UPDATES

Levothyroxine Liquid – agreed Black traffic light as standard tablets can be dispersed in water which is a more cost effective option. **Traffic Light: BLACK**

Hydroxycarbamide – currently Red in formulary. It is amber in the CCG service spec for high risk drugs but there is no formal shared care document. To obtain consultant view as to appropriate colour classification.

Nifedipine MR Tablets – add to formulary for anti natal and post natal hypertension in line with NICE clinical guideline. **Traffic Light: AMBER**

Enalapril – add to formulary for post natal hypertension in line with NICE clinical guideline. **Traffic Light: AMBER**

Tramadol – Marol Prolonged Release Tablets – to be included as preferred option when sustained release preparation is required. **Traffic Light: GREEN**

Gabapentin Liquid – assign Black traffic light. Capsules can be opened. **Traffic Light: BLACK**

Pregabalin Liquid – assign Black traffic light. Capsules can be opened. **Traffic Light: BLACK**

Fluorouracil cream (Efudix) – agreed to change from Amber to Green for actinic keratosis and Bowen's disease. **Traffic Light: GREEN**

Aripiprazole Dispersible tablets – added to formulary for use only when swallowing difficulties. **Traffic Light: AMBER**

2017/098: ELHT ANTIMICROBIAL FORMULARY: SINUSITIS GUIDELINES

New section for antimicrobial formulary that has been agreed with ENT. Approved for use.

Resolved: ELHT Sinusitis Guidelines approved for use.

2017/099: ELHT: VENOUS THROMBOEMBOLISM (VTE): DIAGNOSIS & MANAGEMENT (NON-OBSTETRIC)

The VTE guidelines have been updated.

A question was raised about follow up for potential causes (ie cancer, thrombophilia) – if required, who should carry this out. VG to take back for clarification.

Also general comment about starting rivaroxaban before d-dimer in primary care if not possible to send sample off the same day. LR to follow up.

Resolved: Clarity on follow up and starting rivaroxaban in primary care to be obtained.

2017/100: ELHE: MEDICINES TRANSFER DOCUMENTS FOR CARE HOMES

Revised transfer documents for patients transferring from care homes to hospital. LR to take them to CCG Care Home Team for discussion.

Resolved: LR discuss document with Care Home Team and feedback.

2017/101: ASTHMA ACTION PLANS FOR PAEDIATRICS

Paediatric Respiratory Group recommends all three documents (Asthma UK 'My Asthma Plan' & Your asthma action plan' and Monkey wellbeing 'My asthma/wheeze plan) as options for use with patents and children. All accepted for use as the plans appear to be targeted at different age groups.

Resolved: Three paediatric asthma plans accepted for use.

2017/102: NICE RECOMMENDATIONS (from April)

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TAG 446) recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TAG 447) recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs fund

Traffic Light: RED

Etelcalcetide for treating secondary hyperparathyroidism (TAG 448) recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned

Traffic Light: RED

Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TAG 449) recommended as an option by NICE.

Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TAG 450) recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TAG 451) recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

2107/103 EAMS:

Raxone 150 mg film-coated tablets (idebenone) as treatment for slowing the decline of respiratory function in patients with Duchenne Muscular Dystrophy (DMD)

Acknowledged by ELMMB.

Traffic Light: RED

Any other Business:

Contiform Device – included in Joint Continence and catheter care formulary as red but GP's are being requested to supply. LR to send comments to continence group.

STANDING ITEMS

2017/104: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – June 2017

Minutes acknowledged

2017/105: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – April 2017

Minutes acknowledged

DATE OF NEXT MEETING – Next meeting is **Wednesday 20th September 2017 12.30pm**, Seminar Room 9, Learning and Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 19th JULY 2017

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2017/041	Tolvaptan/Demeclocycline for Hyponatraemia – endocrinologist to be asked to review demeclocycline use	VG	Sept 17
2017/096	LMMG Recommendations (from June) Vitamin D Position Statement – review ELHE paediatric and adult guidelines with LMMG position statement.	LR/JV	Sept 17
2017/099	ELHT: Venous Thromboembolism (VTE): Diagnosis & Management (Non-Obstetric) – clarify who carries out follow up for causes. Primary Care Pathway – starting of rivaroxaban	VG LR	Sept 17
2017/100	ELHE: Medicines Transfer Documents For Care Homes – take to care home team for discussion	LR	Sept 17